Medications for Pulmonary Hypertension
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Pulmonary Hypertension.
Found 2 Approved Drugs for Pulmonary Hypertension
Aspart
Brand Names
Treprostinil, Tyvaso, Remodulin, Yutrepia, Orenitram, Tyvaso DPI, NovoLog, Merilog, FiAsp
Aspart
Brand Names
Treprostinil, Tyvaso, Remodulin, Yutrepia, Orenitram, Tyvaso DPI, NovoLog, Merilog, FiAsp
Form: Injection, Inhalant, Tablet, Kit, Capsule
Method of administration: Subcutaneous, Intravenous, Respiratory (inhalation), Oral
FDA approval date: August 27, 2001
Classification: Prostacycline Vasodilator
Treprostinil injection is a prostacyclin mimetic indicated for: Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).
Adempas
Generic Name
Riociguat
Adempas
Generic Name
Riociguat
Form: Tablet
Method of administration: Oral
FDA approval date: October 08, 2013
Classification: Soluble Guanylate Cyclase Stimulator
Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class.
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances